Lymphoma & Plasma Cell Disorders
News
T-cell therapy produces durable responses in rel/ref HL
Engineered T cells can produce durable responses in patients with Epstein Barr virus–positive (EBV+), relapsed/refractory Hodgkin lymphoma (HL),...
News
Treatment costs threaten cancer program growth
Treatment costs are the greatest threat to the growth of cancer programs, according to a survey of nearly 300 cancer program administrators and...
News
Technique could aid treatment of CLL
Researchers say they have developed a new technique for assessing chromosomal abnormalities in chronic lymphocytic leukemia (CLL). The team...
News
EC authorizes brentuximab vedotin for CTCL
The European Commission (EC) has extended the conditional marketing authorization for brentuximab vedotin (Adcetris®). The drug is now approved...
News
Ofatumumab to be pulled from non-US markets
Novartis is planning to stop marketing ofatumumab (Arzerra®) outside the US, but the drug will still be available for certain patients. The...
News
Bright light therapy improves sleep in cancer survivors
Results of a pilot study suggest that systematic bright light exposure can improve sleep in fatigued cancer survivors. Subjects who were exposed...
News
Risks of MGUS persist beyond 30 years
A long-term study showed that patients with monoclonal gammopathy of undetermined significance (MGUS) were still at risk of progressing to other...
News
CAR T-cell therapy on fast track in US, EU
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah, formerly CTL019) is getting fast-tracked in the United States (US)...
News
FDA grants priority review to CAR T-cell therapy for DLBCL
The application for tisagenlecleucel suspension is based on results from the phase 2 JULIET trial.
News
Drug’s label updated to include risk of allergic reactions
The US Food and Drug Administration (FDA) and Tesaro, Inc., have updated the prescribing information for Varubi® (rolapitant) injectable emulsion...
News
Generic bortezomib available in US
Fresenius Kabi has introduced its generic version of Velcade, Bortezomib for Injection, to the US market. This is the first intravenous...